The U.K. National Institute for Health and Clinical Excellence recommended Eli Lilly and Co.'s Bydureon for National Health Service use as once-weekly treatment of type 2 diabetes. The injectable drug is a long-acting
formulation of Lilly's twice-daily Byetta. A clinical study found that 77% of patients given a weekly dose maintained ideal blood glucose level, compared with 61% of those injected daily.

Related Summaries